GM, Ford, and Stellantis shares climb on news of potential tariff exemptions for U.S. vehicles, signaling a policy shift.
Singapore-based security firm Concorde International Group sees massive trading volume without any apparent news catalyst, prompting investor caution.
Government award will advance the company's non-vaccine influenza therapeutic, CD388, and onshore its manufacturing ahead of a potential pandemic.
Regulators expedite review for ALTO-101, targeting a key aspect of schizophrenia with no currently approved treatments.
Internal U.S. Army memo flags 'fundamental security' vulnerabilities in a key battlefield communications network, raising contract concerns.
Shares of the recently-listed marine fuel provider hit all-time lows on massive volume as the market reacts to unspecified executive shifts.
Blaze at the massive El Segundo facility, a key fuel supplier for Southern California, raises concerns over potential price impacts.
Settlement with Dr. Reddy's Laboratories shields key drugs NEXLETOL and NEXLIZET from generic competition until 2040, boosting investor confidence.